Gioia Colafigli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab	ANNALS OF HEMATOLOGY	2020
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients	ANNALS OF HEMATOLOGY	2020
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice	EXPERT REVIEW OF HEMATOLOGY	2020
Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2020
Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience	ANNALS OF HEMATOLOGY	2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance	LEUKEMIA & LYMPHOMA	2020
The advantages and risks of ruxolitinib for the treatment of polycythemia vera	EXPERT REVIEW OF HEMATOLOGY	2020
Balanced and unbalanced chromosomal translocations in myelodysplastic syndromes: clinical and prognostic significance	LEUKEMIA & LYMPHOMA	2020
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia	THERAPEUTIC ADVANCES IN HEMATOLOGY	2019
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life	ANNALS OF HEMATOLOGY	2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice	ANNALS OF HEMATOLOGY	2019
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib	ONCOLOGY RESEARCH AND TREATMENT	2019
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia	THERAPEUTIC ADVANCES IN HEMATOLOGY	2019
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice	ANNALS OF HEMATOLOGY	2019
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib	ONCOLOGY RESEARCH AND TREATMENT	2019
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life	ANNALS OF HEMATOLOGY	2019
Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome	HEMATOLOGICAL ONCOLOGY	2019
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib	ONCOTARGET	2018
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events	ANNALS OF HEMATOLOGY	2018
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?	EUROPEAN JOURNAL OF HAEMATOLOGY	2018